Clarivate

SEPTEMBER 5, 2024

1: CMS obtained steep price cuts in its first round of negotiations Source: The Centers for Medicare & Medicaid Services By 2027, 20 additional drugs per year will be negotiated, including often complex and expensive physician-administered Medicare Part B drugs, such as infusible biologics.

Insurance 52

Insurance Marketing Manufacturing Prescription 52

pharmaphorum

SEPTEMBER 30, 2022

In March, the first advisory committee agreed with the opinion voiced by the FDA reviewer that there were doubts about the efficacy of Relyvrio, and that it would be preferable to wait for the results of an ongoing, larger study – now expected to read out in 2024.

FDA 84

FDA Doctors Patients Prescription 84

PM360

JUNE 24, 2024

prescriptions, medical devices, or other treatments). 1 Essentially, just because a physician prescribes a therapy, it is not a foregone conclusion that the patient will be covered by insurance. No one actually knows for sure until the prescription is sent for prior authorization.

Education 52

Education Patients Insurance Prescription 52

PM360

AUGUST 7, 2024

While prescription lift is top of mind for many, brands can also drive physician awareness and impact behavioral change. Remember–physicians can be consumers too, so be mindful in understanding how you’re connecting personal and professional data to show impact and inform future engagement.

Media 52

Media Education Physicians Marketing 52

PM360

APRIL 7, 2023

This is especially significant for manufacturers of high-cost specialty drugs, who will now face a recurring additional 20% charge on virtually every prescription fill. On the other side, drug manufacturers are facing the squeeze, with caps on price inflation and a mandated 20% discount in the catastrophic phase.

Manufacturing 97

Manufacturing Insurance Government Marketing 97

Pharmaceutical Representative Training

JUNE 22, 2024

In an effort to reduce the hazards connected with their use, regulations seek to regulate the prescription and distribution of these drugs. 2024) Occupational Outlook Handbook: Wholesale and Manufacturing Sales Representatives. Novartis Pays Over $642 Million to Settle Allegations of Improper Payments to Patients and Physicians.

Sales 52

Sales Pharmaceutical Ethics Pharmaceutical Sales 52

PM360

DECEMBER 20, 2023

A significant battle for the hearts and minds of healthcare professionals (HCPs) will play out in social media during 2024. Fifty percent of responders said they changed prescriptions because of social media information. Expect the demand for MSLs to assist the promotional side of the business to continue and expand.

Media 122

Media Physicians Pharma reps Pharma Rep 122

Pharmaceutical Technology

DECEMBER 4, 2022

Biosimilars with this designation are beneficial to payers as they eliminate the need for another prescription, she explains An interchangeable biosimilar can be automatically substituted for Humira at a pharmacy, Bhat adds. Samsung Bioepis and Organon previously stated that Hadlima's interchangeability data should be ready in 2024.

Marketing 104

Marketing Physicians Competition Patients 104

Clarivate

AUGUST 20, 2024

Moreover, the initial set of negotiated prices represents the first step of a process that eventually will reshape the pricing and reimbursement landscape for prescription drugs under Medicare as CMS gradually replaces private payers as the chief negotiating partner for some of the drug industry’s largest-selling treatments.

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52

Clarivate

OCTOBER 17, 2024

Since the government first created a Part D benefit with the Medicare Modernization Act of 2003 (MMA) , Democrats have agitated for greater governmental input into the cost of prescription drugs for Medicare beneficiaries. Such a change would sharply increase the number of people covered under this program.

Healthcare 52

Healthcare Healthcare Government Insurance 52